JP2009511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511632A5
JP2009511632A5 JP2008536724A JP2008536724A JP2009511632A5 JP 2009511632 A5 JP2009511632 A5 JP 2009511632A5 JP 2008536724 A JP2008536724 A JP 2008536724A JP 2008536724 A JP2008536724 A JP 2008536724A JP 2009511632 A5 JP2009511632 A5 JP 2009511632A5
Authority
JP
Japan
Prior art keywords
composition
retinal
disease
kit
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008536724A
Other languages
English (en)
Japanese (ja)
Other versions
JP5745208B2 (ja
JP2009511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/040429 external-priority patent/WO2007047607A2/en
Publication of JP2009511632A publication Critical patent/JP2009511632A/ja
Publication of JP2009511632A5 publication Critical patent/JP2009511632A5/ja
Application granted granted Critical
Publication of JP5745208B2 publication Critical patent/JP5745208B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008536724A 2005-10-18 2006-10-17 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療 Expired - Fee Related JP5745208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72820905P 2005-10-18 2005-10-18
US60/728,209 2005-10-18
PCT/US2006/040429 WO2007047607A2 (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013213746A Division JP2014028855A (ja) 2005-10-18 2013-10-11 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療

Publications (3)

Publication Number Publication Date
JP2009511632A JP2009511632A (ja) 2009-03-19
JP2009511632A5 true JP2009511632A5 (https=) 2009-11-12
JP5745208B2 JP5745208B2 (ja) 2015-07-08

Family

ID=37872252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008536724A Expired - Fee Related JP5745208B2 (ja) 2005-10-18 2006-10-17 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療
JP2013213746A Withdrawn JP2014028855A (ja) 2005-10-18 2013-10-11 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013213746A Withdrawn JP2014028855A (ja) 2005-10-18 2013-10-11 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療

Country Status (11)

Country Link
US (5) US8062657B2 (https=)
EP (1) EP1937210B1 (https=)
JP (2) JP5745208B2 (https=)
KR (1) KR101430760B1 (https=)
CN (1) CN101394834A (https=)
AU (1) AU2006304416B2 (https=)
BR (1) BRPI0613401B8 (https=)
CA (1) CA2602577C (https=)
MX (2) MX339797B (https=)
NZ (1) NZ562032A (https=)
WO (1) WO2007047607A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
MX339797B (es) * 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
PL2214646T3 (pl) 2007-10-05 2021-12-20 Wayne State University Dendrymery do przedłużonego uwalniania związków
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
US10501779B2 (en) * 2011-05-12 2019-12-10 President And Fellows Of Harvard College Oligonucleotide trapping
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
CA2946422C (en) 2014-04-30 2019-03-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN108369611A (zh) * 2015-10-07 2018-08-03 基因泰克公司 用于预测治疗剂-聚合物缀合物的玻璃体半衰期的系统和方法
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
CN106983733A (zh) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用
WO2019043179A1 (en) * 2017-09-01 2019-03-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) COMPOSITIONS FOR THE TREATMENT OF MACULAR EDEMA
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
US12509469B2 (en) 2019-08-07 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
ES2078175B1 (es) * 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
US5646136A (en) 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
ATE493983T1 (de) 1996-11-05 2011-01-15 Childrens Medical Center Thalidomide und dexamethason für die behandlung von tumors
JP2001513369A (ja) * 1997-08-11 2001-09-04 アラーガン・セイルズ・インコーポレイテッド 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1339438B1 (en) * 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
AU2002354205A1 (en) 2001-12-12 2003-06-23 Rhodia Chimie Formulation comprising an ionic compound, a polyionic polymer, a nd a copolymer.
US6873524B2 (en) * 2002-08-15 2005-03-29 Audavi Corporation Data storage device
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2004073607A2 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
DE602005011928D1 (de) * 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
MX339797B (es) * 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
JP2007309763A (ja) 2006-05-18 2007-11-29 Sumitomo Electric Ind Ltd 電線の表面欠陥検出装置

Similar Documents

Publication Publication Date Title
JP2009511632A5 (https=)
RU2521338C9 (ru) Способ лечения атрофической возрастной макулярной дегенерации
RU2664686C2 (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
JP5484911B2 (ja) 眼内使用のための環状脂質インプラントの製造法
ES2658175T3 (es) Implantes intracamerales de agentes terapéuticos de liberación sostenida
US10959954B2 (en) Dexamethasone prodrug compositions and uses thereof
JP2008505978A (ja) 眼病用組成物および眼病治療法
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
CA3096838A1 (en) Methods and compositions for sustained release microparticles for ocular drug delivery
US12473326B2 (en) Crystalline forms of dexamethasone dimers and uses thereof
JP2018503736A (ja) 眼内圧を抑える抗緑内障剤の持続放出のための組成物
CA2598095A1 (en) Method of relieving or avoiding side effect of steroid
JP2013501794A (ja) 目の疾患を治療するためのイソチオゾール
WO2021237096A1 (en) Durable implants and microparticles for long-term ocular therapy
US20110257186A1 (en) Compositions and methods for treating visual disorders
US20250367130A1 (en) Thermoresponsive hydrogel containing metal-organic framework particles for noninvasive ocular drug delivery